Symbols / RIGL Stock $30.25 -0.17% Rigel Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
RIGL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Raul R. Rodriguez
Exch · Country NMS · United States
Market Cap 559.69M
Enterprise Value 458.72M
Income 364.23M
Sales 299.77M
FCF (ttm) 78.55M
Book/sh 21.64
Cash/sh 7.93
Employees 172
Insider 10d —
IPO Nov 29, 2000
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 1.57
Forward P/E 6.60
PEG —
P/S 1.87
P/B 1.40
P/C —
EV/EBITDA 3.61
EV/Sales 1.53
Quick Ratio 2.20
Current Ratio 2.62
Debt/Eq 11.43
LT Debt/Eq —
EPS (ttm) 19.29
EPS next Y 4.58
EPS Growth -30.20%
Revenue Growth 10.30%
EPS Gr Q/Q -24.40%
Rev Gr Q/Q —
Earnings (next) 2026-08-04
Earnings (prior) 2026-05-05
ROA 22.88%
ROE 174.08%
ROIC —
Gross Margin 81.20%
Oper. Margin 20.21%
Profit Margin 121.50%
Shs Outstand 18.50M
Shs Float 15.94M
Insider Own 3.26%
Instit Own 94.59%
Short Float 21.90%
Short Ratio 9.18
Short Interest 3.95M
52W High 52.24
vs 52W High -42.09%
52W Low 18.14
vs 52W Low 66.76%
Beta 1.18
Impl. Vol. 0.78%
Rel Volume 0.53
Avg Volume 384.07K
Volume 203.84K
Target (mean) $53.20
Tgt Median $50.00
Tgt Low $38.00
Tgt High $81.00
# Analysts 5
Recom Buy
Prev Close $30.30
Price $30.25
Change -0.17%
About

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$53.20
Mean price target
2. Current target
$30.25
Latest analyst target
3. DCF / Fair value
$76.42
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$30.25
Low
$38.00
High
$81.00
Mean
$53.20

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-02 reit HC Wainwright & Co. Buy → Buy $57
2026-05-27 reit HC Wainwright & Co. Buy → Buy $57
2026-05-22 reit HC Wainwright & Co. Buy → Buy $57
2026-05-13 main Citigroup Buy → Buy $81
2026-05-07 main Citigroup Buy → Buy $69
2025-11-05 up Jefferies Hold → Buy $42
2025-11-05 main Cantor Fitzgerald Neutral → Neutral $38
2025-10-08 reit HC Wainwright & Co. Buy → Buy $57
2025-08-06 main Cantor Fitzgerald Neutral → Neutral $32
2025-05-07 main Cantor Fitzgerald Neutral → Neutral $23
2025-03-06 main Citigroup Buy → Buy $55
2025-03-05 main B. Riley Securities Neutral → Neutral $24
2025-03-05 reit HC Wainwright & Co. Buy → Buy $57
2025-01-23 reit HC Wainwright & Co. Buy → Buy $57
2025-01-22 reit HC Wainwright & Co. Buy → Buy $57
2025-01-14 reit HC Wainwright & Co. Buy → Buy $57
2024-12-10 main Cantor Fitzgerald Neutral → Neutral $25
2024-12-10 main B. Riley Securities Neutral → Neutral $20
2024-12-10 reit HC Wainwright & Co. Buy → Buy $57
2024-12-06 main B. Riley Securities Neutral → Neutral $27
News
RSS: Latest RIGL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-26 ALI-JACKSON KAMIL Director — 2,500 $29.17 $72,925
2026-05-15 MOOS WALTER H Director — 5,750 $0.00 $0
2026-05-15 MILLER MICHAEL PATRICK Director — 5,750 $0.00 $0
2026-05-15 FROHLICH MARK W Director — 5,750 $0.00 $0
2026-05-15 LAPOINTE ANTHONY GREGG Director — 5,750 $0.00 $0
2026-05-15 WASMAN JANE Director — 5,750 $0.00 $0
2026-05-15 HANNAH ALISON L. Director — 5,750 $0.00 $0
2026-05-15 ALI-JACKSON KAMIL Director — 5,750 $0.00 $0
2026-02-20 MOOS WALTER H Director — 4,000 $24.00 $96,000
2026-02-20 MOOS WALTER H Director — 4,000 $36.36 $145,440
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
294.28
+64.15%
179.28
+53.38%
116.88
-2.79%
120.24
Operating Revenue
372.26
+52.38%
244.30
+53.03%
159.65
+5.00%
152.05
Cost Of Revenue
19.62
+5.22%
18.65
+162.26%
7.11
+306.52%
1.75
Reconciled Cost Of Revenue
19.62
+5.22%
18.65
+162.26%
7.11
+306.52%
1.75
Gross Profit
274.66
+70.99%
160.63
+46.33%
109.77
-7.36%
118.49
Operating Expense
149.19
+9.35%
136.44
+4.74%
130.26
-24.58%
172.72
Research And Development
33.30
+42.41%
23.38
-4.66%
24.52
-59.31%
60.27
Selling General And Administration
115.90
+2.51%
113.06
+6.92%
105.74
-5.97%
112.45
Total Expenses
168.82
+8.85%
155.09
+12.89%
137.37
-21.26%
174.47
Operating Income
125.47
+418.63%
24.19
+218.06%
-20.49
+62.21%
-54.23
Total Operating Income As Reported
125.47
+418.63%
24.19
+218.06%
-20.49
+63.11%
-55.55
EBITDA
131.56
+361.43%
28.51
+267.91%
-16.98
+68.48%
-53.87
Normalized EBITDA
131.56
+361.43%
28.51
+267.91%
-16.98
+67.68%
-52.55
Reconciled Depreciation
2.42
+8.39%
2.23
+79.97%
1.24
+24.05%
1.00
EBIT
129.15
+391.35%
26.28
+244.27%
-18.22
+66.79%
-54.87
Total Unusual Items
—
0.00
0.00
+100.00%
-1.32
Total Unusual Items Excluding Goodwill
—
0.00
0.00
+100.00%
-1.32
Special Income Charges
—
0.00
0.00
+100.00%
-1.32
Restructuring And Mergern Acquisition
—
0.00
0.00
-100.00%
1.32
Net Income
367.02
+1999.08%
17.48
+169.69%
-25.09
+57.16%
-58.57
Pretax Income
121.83
+563.33%
18.37
+173.20%
-25.09
+57.16%
-58.57
Net Non Operating Interest Income Expense
-3.64
+37.54%
-5.83
-26.65%
-4.60
-52.17%
-3.02
Interest Expense Non Operating
7.32
-7.55%
7.92
+15.22%
6.87
+85.38%
3.71
Net Interest Income
-3.64
+37.54%
-5.83
-26.65%
-4.60
-52.17%
-3.02
Interest Expense
7.32
-7.55%
7.92
+15.22%
6.87
+85.38%
3.71
Interest Income Non Operating
3.68
+75.96%
2.09
-7.92%
2.27
+232.16%
0.68
Interest Income
3.68
+75.96%
2.09
-7.92%
2.27
+232.16%
0.68
Other Income Expense
—
—
—
-1.32
Tax Provision
-245.20
-27931.67%
0.88
0.00
0.00
Tax Rate For Calcs
0.00
+337.50%
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
+100.00%
-0.00
Net Income Including Noncontrolling Interests
367.02
+1999.08%
17.48
+169.69%
-25.09
+57.16%
-58.57
Net Income From Continuing Operation Net Minority Interest
367.02
+1999.08%
17.48
+169.69%
-25.09
+57.16%
-58.57
Net Income From Continuing And Discontinued Operation
367.02
+1999.08%
17.48
+169.69%
-25.09
+57.16%
-58.57
Net Income Continuous Operations
367.02
+1999.08%
17.48
+169.69%
-25.09
+57.16%
-58.57
Normalized Income
367.02
+1999.08%
17.48
+169.69%
-25.09
+56.18%
-57.25
Net Income Common Stockholders
367.02
+1999.08%
17.48
+169.69%
-25.09
+57.16%
-58.57
Diluted EPS
19.48
+1867.68%
0.99
+168.75%
-1.44
+57.65%
-3.40
Basic EPS
20.40
+1960.61%
0.99
+168.75%
-1.44
+57.65%
-3.40
Basic Average Shares
17.99
+2.32%
17.58
+1.02%
17.40
+0.93%
17.24
Diluted Average Shares
18.84
+6.52%
17.69
+1.64%
17.40
+0.93%
17.24
Diluted NI Availto Com Stockholders
367.02
+1999.08%
17.48
+169.69%
-25.09
+57.16%
-58.57
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
513.59
+213.21%
163.98
+39.88%
117.22
-12.70%
134.28
Current Assets
240.17
+77.77%
135.10
+36.10%
99.27
-14.35%
115.90
Cash Cash Equivalents And Short Term Investments
154.96
+100.40%
77.32
+35.81%
56.93
-2.19%
58.21
Cash And Cash Equivalents
40.58
-28.49%
56.75
+73.08%
32.79
+34.04%
24.46
Other Short Term Investments
114.38
+455.89%
20.57
-14.79%
24.15
-28.45%
33.75
Receivables
51.76
+24.39%
41.62
+36.22%
30.55
-24.23%
40.32
Accounts Receivable
51.76
+24.39%
41.62
+36.22%
30.55
-24.23%
40.32
Gross Accounts Receivable
52.10
+24.46%
41.86
+36.22%
30.73
—
Allowance For Doubtful Accounts Receivable
-0.34
-37.40%
-0.25
-36.67%
-0.18
—
Inventory
11.51
+91.70%
6.00
+8.69%
5.52
-39.44%
9.12
Raw Materials
—
—
—
4.55
Work In Process
—
—
—
2.66
Finished Goods
—
—
—
1.90
Prepaid Assets
16.73
+196.61%
5.64
—
—
Other Current Assets
5.21
+15.12%
4.52
-27.76%
6.26
-24.19%
8.26
Total Non Current Assets
273.43
+847.00%
28.87
+60.77%
17.96
-2.27%
18.38
Net PPE
0.92
+273.98%
0.25
-76.02%
1.03
-63.19%
2.79
Gross PPE
0.92
+273.98%
0.25
-90.99%
2.73
-79.92%
13.59
Accumulated Depreciation
—
-0.26
+84.68%
-1.70
+84.23%
-10.81
Properties
—
—
0.00
0.00
Machinery Furniture Equipment
—
0.15
-57.85%
0.36
-82.28%
2.05
Construction In Progress
—
—
—
0.07
Other Properties
0.92
+273.98%
0.25
-89.61%
2.37
-74.92%
9.44
Leases
—
—
0.00
-100.00%
2.11
Goodwill And Other Intangible Assets
24.75
-8.68%
27.10
+95.27%
13.88
-7.16%
14.95
Non Current Deferred Assets
245.85
0.00
—
—
Non Current Deferred Taxes Assets
245.85
0.00
—
—
Other Non Current Assets
1.91
+24.95%
1.53
-50.02%
3.06
+377.34%
0.64
Total Liabilities Net Minority Interest
122.11
-24.01%
160.69
+10.16%
145.87
-1.37%
147.90
Current Liabilities
99.24
+56.77%
63.30
+18.83%
53.27
-18.32%
65.21
Payables And Accrued Expenses
22.83
+28.18%
17.81
+11.38%
15.99
-56.43%
36.70
Payables
7.19
+115.36%
3.34
-53.25%
7.14
-68.27%
22.51
Accounts Payable
7.19
+115.36%
3.34
-53.25%
7.14
-68.27%
22.51
Current Accrued Expenses
15.63
+8.06%
14.47
+63.55%
8.85
-37.67%
14.19
Pensionand Other Post Retirement Benefit Plans Current
11.91
+17.51%
10.14
+16.86%
8.68
-2.14%
8.87
Current Debt And Capital Lease Obligation
30.43
+302.62%
7.56
-4.60%
7.92
+599.12%
1.13
Current Debt
29.81
+309.96%
7.27
+0.59%
7.23
—
Other Current Borrowings
29.81
+309.96%
7.27
+0.59%
7.23
—
Current Capital Lease Obligation
0.61
+115.44%
0.28
-58.82%
0.69
-38.92%
1.13
Current Deferred Liabilities
29.07
+4.59%
27.80
+63.13%
17.04
+26.08%
13.51
Current Deferred Revenue
29.07
+4.59%
27.80
+63.13%
17.04
+26.08%
13.51
Other Current Liabilities
5.00
—
3.64
-27.12%
5.00
Total Non Current Liabilities Net Minority Interest
22.88
-76.51%
97.39
+5.17%
92.60
+12.00%
82.68
Long Term Debt And Capital Lease Obligation
22.88
-56.35%
52.41
-0.47%
52.66
+30.28%
40.42
Long Term Debt
22.48
-57.10%
52.41
+0.07%
52.37
+32.76%
39.45
Long Term Capital Lease Obligation
0.40
0.00
-100.00%
0.28
-70.68%
0.97
Other Non Current Liabilities
—
44.98
+12.61%
39.94
-5.49%
42.26
Stockholders Equity
391.48
+11806.33%
3.29
+111.48%
-28.64
-110.37%
-13.62
Common Stock Equity
391.48
+11806.33%
3.29
+111.48%
-28.64
-110.37%
-13.62
Capital Stock
0.02
+0.00%
0.02
+5.88%
0.02
-90.23%
0.17
Common Stock
0.02
+0.00%
0.02
+5.88%
0.02
-90.23%
0.17
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
18.31
+3.39%
17.71
+1.30%
17.48
+0.82%
17.34
Ordinary Shares Number
18.31
+3.39%
17.71
+1.30%
17.48
+0.82%
17.34
Additional Paid In Capital
1,414.32
+1.51%
1,393.33
+1.05%
1,378.88
+0.73%
1,368.82
Retained Earnings
-1,023.04
+26.40%
-1,390.07
+1.24%
-1,407.55
-1.81%
-1,382.46
Gains Losses Not Affecting Retained Earnings
0.18
+1710.00%
0.01
+25.00%
0.01
+105.23%
-0.15
Other Equity Adjustments
0.18
+1710.00%
0.01
+25.00%
0.01
+105.23%
-0.15
Total Equity Gross Minority Interest
391.48
+11806.33%
3.29
+111.48%
-28.64
-110.37%
-13.62
Total Capitalization
413.96
+643.25%
55.70
+134.72%
23.73
-8.14%
25.83
Working Capital
140.93
+96.27%
71.80
+56.10%
46.00
-9.26%
50.69
Invested Capital
443.77
+604.76%
62.97
+103.40%
30.96
+19.84%
25.83
Total Debt
53.30
-11.11%
59.97
-1.01%
60.58
+45.79%
41.55
Net Debt
11.71
+299.25%
2.93
-89.06%
26.82
+78.90%
14.99
Capital Lease Obligations
1.01
+254.04%
0.28
-70.83%
0.98
-53.59%
2.10
Net Tangible Assets
366.73
+1640.11%
-23.81
+44.00%
-42.52
-48.86%
-28.57
Tangible Book Value
366.73
+1640.11%
-23.81
+44.00%
-42.52
-48.86%
-28.57
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
75.66
+140.40%
31.47
+647.99%
-5.74
+92.21%
-73.76
Cash Flow From Continuing Operating Activities
75.66
+140.40%
31.47
+647.99%
-5.74
+92.21%
-73.76
Net Income From Continuing Operations
367.02
+1999.08%
17.48
+169.69%
-25.09
+57.16%
-58.57
Depreciation Amortization Depletion
2.42
+8.39%
2.23
+79.97%
1.24
+24.05%
1.00
Depreciation And Amortization
2.42
+8.39%
2.23
+79.97%
1.24
+24.05%
1.00
Other Non Cash Items
-39.98
—
—
0.68
Stock Based Compensation
12.71
+2.57%
12.39
+40.73%
8.81
-28.90%
12.38
Deferred Tax
-245.85
0.00
0.00
—
Deferred Income Tax
-245.85
0.00
0.00
—
Operating Gains Losses
—
-0.08
-129.70%
0.27
+292.75%
-0.14
Gain Loss On Sale Of PPE
0.00
+100.00%
-0.08
-129.70%
0.27
+292.75%
-0.14
Change In Working Capital
-19.51
-12852.94%
0.15
-98.39%
9.52
+132.76%
-29.05
Change In Receivables
-10.15
+8.29%
-11.06
-213.25%
9.77
+139.32%
-24.85
Changes In Account Receivables
-10.15
+8.29%
-11.06
-213.25%
9.77
+139.32%
-24.85
Change In Inventory
-5.63
-837.57%
0.76
-34.81%
1.17
+149.31%
-2.38
Change In Prepaid Assets
-11.85
-244.42%
-3.44
-267.48%
2.05
+500.39%
-0.51
Change In Payables And Accrued Expense
5.30
+263.52%
-3.24
+28.90%
-4.56
-261.68%
2.82
Change In Accrued Expense
1.45
+159.11%
0.56
+113.35%
-4.20
-333.82%
-0.97
Change In Payable
3.85
+201.29%
-3.80
-939.07%
-0.37
-109.66%
3.79
Change In Account Payable
3.85
+201.29%
-3.80
-939.07%
-0.37
-109.66%
3.79
Change In Other Working Capital
3.05
-75.03%
12.22
+264.86%
3.35
+184.05%
1.18
Change In Other Current Assets
-0.67
-209.59%
0.61
-42.47%
1.07
-86.25%
7.77
Change In Other Current Liabilities
0.44
-89.80%
4.30
+228.99%
-3.34
+74.50%
-13.08
Investing Cash Flow
-92.36
-2336.44%
4.13
+196.11%
-4.30
-105.90%
72.78
Cash Flow From Continuing Investing Activities
-92.36
-2336.44%
4.13
+196.11%
-4.30
-105.90%
72.78
Net PPE Purchase And Sale
0.00
-100.00%
0.10
-62.16%
0.26
-71.00%
0.89
Purchase Of PPE
—
—
0.00
+100.00%
-0.45
Sale Of PPE
0.00
-100.00%
0.10
-62.16%
0.26
-71.00%
0.89
Capital Expenditure
—
-0.40
+97.36%
-15.00
-3233.33%
-0.45
Capital Expenditure Reported
0.00
+100.00%
-0.04
0.00
+100.00%
-0.45
Net Investment Purchase And Sale
-92.36
-2185.93%
4.43
-57.60%
10.44
-85.56%
72.33
Purchase Of Investment
-153.49
-335.17%
-35.27
-13.03%
-31.21
-8.00%
-28.89
Sale Of Investment
61.13
+53.98%
39.70
-4.68%
41.65
-58.86%
101.23
Net Intangibles Purchase And Sale
0.00
+100.00%
-0.36
+97.60%
-15.00
0.00
Purchase Of Intangibles
0.00
+100.00%
-0.36
+97.60%
-15.00
0.00
Financing Cash Flow
0.60
+105.16%
-11.64
-163.38%
18.37
+180.41%
6.55
Cash Flow From Continuing Financing Activities
0.60
+105.16%
-11.64
-163.38%
18.37
+180.41%
6.55
Net Issuance Payments Of Debt
-7.50
0.00
-100.00%
19.95
+2.09%
19.54
Issuance Of Debt
0.00
0.00
-100.00%
19.95
+2.09%
19.54
Repayment Of Debt
-7.50
0.00
0.00
—
Long Term Debt Issuance
0.00
0.00
-100.00%
19.95
+2.09%
19.54
Long Term Debt Payments
-7.50
0.00
0.00
—
Net Long Term Debt Issuance
-7.50
0.00
-100.00%
19.95
+2.09%
19.54
Net Common Stock Issuance
0.00
+100.00%
-10.00
0.00
0.00
Common Stock Payments
0.00
+100.00%
-10.00
0.00
0.00
Repurchase Of Capital Stock
0.00
+100.00%
-10.00
0.00
0.00
Proceeds From Stock Option Exercised
8.10
+312.47%
1.96
+87.23%
1.05
-50.61%
2.12
Net Other Financing Charges
—
-3.60
-36.97%
-2.63
+82.59%
-15.12
Changes In Cash
-16.11
-167.23%
23.96
+187.74%
8.33
+49.52%
5.57
Beginning Cash Position
56.75
+73.08%
32.79
+34.04%
24.46
+29.48%
18.89
End Cash Position
40.64
-28.39%
56.75
+73.08%
32.79
+34.04%
24.46
Free Cash Flow
75.66
+143.46%
31.07
+249.81%
-20.74
+72.05%
-74.21
Interest Paid Supplemental Data
6.57
-6.62%
7.04
+20.37%
5.85
+134.39%
2.50
Income Tax Paid Supplemental Data
1.06
+221.15%
0.33
+308.64%
0.08
0.00
Amortization Of Securities
-1.15
-62.20%
-0.71
-48.02%
-0.48
-660.32%
-0.06
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category